Examkin

Question

Difficulty: HardSchizophrenia and Psychotic Disorders

A 32-year-old man with a 10-year history of treatment-resistant schizophrenia is evaluated on the inpatient psychiatric unit. Over the past several years, he has continued to experience severe, commanding auditory hallucinations despite adequate therapeutic trials of risperidone, olanzapine, and haloperidol. Four weeks ago, he was transitioned to clozapine, which was gradually titrated to 600 mg daily. The nursing staff notes that his psychotic symptoms have dramatically improved, and he is interacting appropriately with peers for the first time in years. However, earlier today, the patient experienced a new-onset generalized tonic-clonic seizure that lasted 90 seconds and spontaneously resolved. He has no prior history of seizures, and a non-contrast head CT is unremarkable. His current absolute neutrophil count is 4,500/mm³. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. A
    Add carbamazepine and maintain the clozapine dose
  2. Add valproic acid and reduce the clozapine doseAnswer
  3. C
    Discontinue clozapine and begin chlorpromazine
  4. D
    Discontinue clozapine and begin ziprasidone
  5. E
    Add phenytoin and maintain the clozapine dose

Answer

Add valproic acid and reduce the clozapine dose
The correct approach is to reduce the clozapine dose and add valproic acid. This patient has treatment-resistant schizophrenia and is showing significant clinical improvement on clozapine. Clozapine is highly effective for refractory cases but carries a known, dose-dependent risk of seizures, particularly at doses greater than 600 mg daily. When a seizure occurs in a patient deriving substantial psychiatric benefit from clozapine, the medication should not be abandoned. Instead, the standard of care is to lower the dose to reduce the seizure threshold risk and concurrently initiate an antiepileptic drug. Valproic acid is the anticonvulsant of choice because it provides excellent broad-spectrum coverage and does not cause bone marrow suppression, avoiding a dangerous synergistic interaction with clozapine.

Step-by-Step Solution

1
Identify the etiology of the new-onset seizure in this patient.
The seizure is an adverse effect of high-dose clozapine (600 mg daily).
Clozapine lowers the seizure threshold in a strong, dose-dependent manner.
2
Determine whether clozapine should be discontinued.
Clozapine should be continued with adjustments.
The patient has treatment-resistant schizophrenia and is experiencing significant improvement for the first time; the side effect can be managed without completely abandoning the drug.
3
Select the appropriate pharmacologic management for the seizure.
Reduce the clozapine dose and add valproic acid.
Dose reduction decreases the immediate seizure risk, and valproic acid provides antiepileptic coverage without compounding clozapine's risk of bone marrow suppression.

Key Concept

Management of clozapine-induced seizures in treatment-resistant schizophrenia
Estimated Time:1m 30s
Rate this question

Topics

Schizophrenia and Psychotic Disorders

More questions from this topic